DLL4 Restores Damaged Liver by Enhancing Hbmsc Differentiation into Cholangiocytes

Suwan Sun,Lunzhi Yuan,Zhanglu An,Dongyan Shi,Jiaojiao Xin,Jing Jiang,Keke Ren,Jiaxian Chen,Beibei Guo,Xingping Zhou,Qian Zhou,Xiaojun Jin,Sihan Ruan,Tong Cheng,Ningshao Xia,Jun Li
DOI: https://doi.org/10.1016/j.scr.2020.101900
IF: 1.587
2020-01-01
Stem Cell Research
Abstract:Background & aims: Biliary injury is one of the main pathological mechanisms of fulminant hepatic failure (FHF). Delta-like ligand 4 (DLL4)-mediated Notch activation contributes to reversing biliary injury; however, the specific role of DLL4 in biliary restoration is still unclear. This study aimed to determine whether human bone marrow mesenchymal stem cells (hBMSCs) can differentiate into biliary epithelial cells (cholangiocytes) in vitro and in vivo and to clarify the role of DLL4 in restoring damaged liver by enhancing cholangiocyte differentiation. Methods: hBMSCs were transplanted into immunodeficient mice (FRGS) with FHF induced by the hamster-anti mouse CD95 antibody JO2. The appearance of human cholangiocytes was evaluated in the generated hBMSCFRGS mice by q-PCR expression, flow cytometry and immunohistochemistry. The potency of DLL4 in inducing cholangiocyte differentiation from hBMSCs was assessed by observing the cell morphology and measuring the expression of cholangiocyte-specific genes and proteins. Results: Human KRT19and KRT7-double-positive cholangiocyte-like cells appeared in hBMSC-FRGS mice at 12 weeks after transplantation. After these cells were separated and collected by fluorescent-activated cell sorting (FACS), there were high levels of expression of eight typical human cholangiocyte-specific genes and proteins (e.g., KRT19 and KRT7). Furthermore, hBMSC-derived cholangiocytes induced by DLL4 had a better shape with higher nucleus/cytoplasm ratios and showed a specific increase in the expression of cholangiocytespecific genes and proteins (e.g., KRT19, KRT7, SOX9 and CFTR). Conclusions: Cholangiocytes can be efficiently differentiated from hBMSCs in vivo and in vitro. DLL4 restores damaged liver by enhancing cholangiocyte differentiation from hBMSCs and has the potential to be used in future clinical therapeutic applications.
What problem does this paper attempt to address?